ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MCK | MCKESSON CORP | Healthcare | $124.35B | 23.61% |
2COR | CENCORA INC | Healthcare | $66.67B | 12.66% |
3CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 12.20% |
4ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 9.02% |
5CNC | CENTENE CORP | Healthcare | $34.79B | 6.60% |
6GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 3.98% |
7MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 3.49% |
8BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 2.89% |
9MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 2.08% |
10OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 1.88% |
11HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 1.87% |
12RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 1.45% |
13AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 1.44% |
14IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 1.38% |
15IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 1.23% |
16PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 1.00% |
17SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 1.00% |
18LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 0.99% |
19TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.72% |
20VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 0.67% |
21DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 0.61% |
22PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 0.57% |
23RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.49% |
24SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.44% |
25PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.24B | 0.43% |
26BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.40% |
27REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.40% |
28AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.35% |
29BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.78B | 0.34% |
30SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.31% |
31IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.30% |
32ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.30% |
33NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.27% |
34KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.27% |
35OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.26% |
36URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.25% |
37CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.25% |
38INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.25% |
39ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.23% |
40VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.23% |
41FRNM | FREENOME INC | Healthcare | $1.14B | 0.22% |
42MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.21% |
43VSTM | VERASTEM INC | Healthcare | $1.06B | 0.20% |
44OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.17% |
45NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.13% |
46KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.13% |
47CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.12% |
48SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.12% |
49SRZN | SURROZEN INC | Healthcare | $604M | 0.11% |
50IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.11% |
51CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.10% |
52RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.10% |
53PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.10% |
54PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.08% |
55TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.08% |
56FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.07% |
57BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.06% |
58CV | CAPSOVISION INC | Healthcare | $314M | 0.06% |
59QTTB | Q32 BIO INC | Healthcare | $264M | 0.05% |
60ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.05% |
61LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.05% |
62UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.04% |
63DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.04% |
64GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.04% |
65AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.04% |
66TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.04% |
67KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.04% |
68RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.04% |
69ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.04% |
70STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.03% |
71INGN | INOGEN INC | Healthcare | $146M | 0.03% |
72CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.02% |
73SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.02% |
74IMUX | IMMUNIC INC | Healthcare | $106M | 0.02% |
75CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.02% |
76JYNT | JOINT CORP | Healthcare | $92M | 0.02% |
77RLYB | RALLYBIO CORP | Healthcare | $84M | 0.02% |
78VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.02% |
79NRXS | NEURAXIS INC | Healthcare | $82M | 0.02% |
80ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.02% |
81NTRB | NUTRIBAND INC | Healthcare | $73M | 0.01% |
82GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.01% |
83XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.01% |
84COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.01% |
85YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.01% |
86ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $526.75B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 94% toward Large, 59% toward Growth. +12% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 18%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 13.5% | 5.1% |
| 3 yearsp.a. | 21.7% | 7.0% |
| 5 yearsp.a. | 14.3% | 13.3% |
| 10 yearsp.a. | 16.5% | 9.3% |
| Since inceptionp.a. | 10.2% | 2.7% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 17.2% | 4.9% |
| 2025 | 44.2% | 35.2% |
| 2024 | -0.1% | -11.8% |
| 2023 | 21.2% | 16.5% |
| 2022 | -7.7% | 22.0% |
| 2021 | 23.8% | 28.5% |
| 2020 | 33.9% | 8.5% |
| 2019 | 25.4% | -2.7% |
| 2018 | -8.5% | -7.6% |
| 2017 | 31.8% | 13.1% |
| 2016 | -16.6% | -5.4% |
| 2015 | 7.1% | 5.4% |
| 2014 | 28.3% | -5.2% |
| 2013 | 47.9% | -3.4% |
| 2012 | 15.2% | -7.2% |
| 2011 | 16.4% | 14.0% |
| 2010 | 18.4% | 17.4% |
| 2009 | 31.8% | 8.5% |
| 2008 | -41.3% | -8.9% |
| 2007 | 16.5% | 3.0% |
| 2006 | 10.0% | 2.7% |
| 2005 | 20.1% | 16.2% |
| 2004 | 4.0% | 4.0% |
| 2003 | 47.7% | 8.7% |
| 2002 | -19.1% | 7.6% |
| 2001 | -11.2% | -0.6% |
| 2000 | 14.9% | -35.1% |
| 1999 | -21.6% | -23.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Net Operating Assets Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Net Operating Assets signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.